Lupin Limited has announced a strategic collaboration with TB Alliance to support the clinical development and future commercialization of the investigational drug Telacebec, formerly known as Q203. The drug is being developed to treat multiple mycobacterial diseases, including tuberculosis (TB), leprosy, and Buruli ulcer.
Under the terms of the agreement, TB Alliance will continue to lead the clinical development of Telacebec, while Lupin will contribute its expertise in large-scale manufacturing, regulatory affairs, and global supply chain management. The partnership aims to ensure broader and more equitable global access to the treatment once it progresses through development.
The collaboration focuses on addressing diseases that continue to pose significant public health challenges, particularly in low- and middle-income countries. Tuberculosis remains one of the leading infectious causes of death worldwide, while leprosy and Buruli ulcer are considered neglected tropical diseases with limited treatment options.
Commenting on the development, Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU at Lupin, said the partnership reflects the company’s long-standing commitment to addressing unmet medical needs. He noted that combining Lupin’s manufacturing and distribution capabilities with TB Alliance’s drug development expertise could help deliver timely treatment options to patients affected by these diseases.
Mel Spigelman, MD, President and CEO of TB Alliance, said Telacebec has the potential to significantly improve treatment outcomes for diseases that have historically received limited research attention. He added that working with Lupin would help advance the compound responsibly while strengthening access capabilities across global markets.
